Type / Class
Equity / American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share
Shares outstanding
41.1M
Number of holders
29
Total 13F shares, excl. options
18.8M
Shares change
+1.98M
Total reported value, excl. options
$184M
Value change
+$18.2M
Number of buys
10
Number of sells
-20
Price
$9.79

Significant Holders of Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share (ACHL) as of Q2 2021

36 filings reported holding ACHL - Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share as of Q2 2021.
Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share (ACHL) has 29 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 18.8M shares of 41.1M outstanding shares and own 45.68% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (5.01M shares), BAKER BROS. ADVISORS LP (2.59M shares), Artal Group S.A. (2.26M shares), Redmile Group, LLC (2.09M shares), ORBIMED ADVISORS LLC (1.58M shares), BOXER CAPITAL, LLC (1.54M shares), Farallon Capital Management LLC (997K shares), PERCEPTIVE ADVISORS LLC (755K shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (301K shares), and SPHERA FUNDS MANAGEMENT LTD. (292K shares).
This table shows the top 29 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor Option Weight % Change % Value $ * Price $ Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.